Log in to your Inderes Free account to see all free content on this page.
Gubra
338 DKK -2.87%HC Andersen Capital receives payment from Gubra for a DigitalIR/Corporate Visibility agreement. See disclaimer.
12 investors are following this company
Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They mainly conduct research and development in the field of metabolic and fibrotic diseases. The company's product portfolio includes several brands and pharmaceuticals, and operations are conducted on a global level, with the largest presence in North America and the Nordics. The head office is located in Hørsholm, Denmark.
Revenue
205.01M
EBIT %
-23.25 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
GUBRA
Daily low / high price
336 / 350
DKK
Market cap
5.53B DKK
Turnover
18.38M DKK
Volume
53K
Latest research
Latest videos
Financial calendar
Interim report
23.08.2024
ShowingAll content types
Trading statement Q1-2024: Strong start to the year
Gubra raises financial outlook for 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio